Therapeutic areas in which Haberman Associates principally works include:

  • Oncology
  • Cardiovascular diseases
  • Immune and inflammatory diseases
  • Metabolic diseases
  • Central nervous system (CNS) diseases
Examples of the consulting services we have provided include:
  • Provided strategic planning support and technology assessments for large and small biotechnology companies, major research products companies, and financial services companies. Technology and therapeutic areas included genomics, proteomics, other drug discovery technologies and applications, cancer, metabolic diseases, and infectious diseases.
  • Provided technology, scientific, and medical inputs as a key member of a team developing a technology and market-modeling database for a major pharmaceutical company, to guide resource allocation and new product strategy decisions in the area of diabetes and obesity drugs.
  • Assessed early-stage pipeline drug candidates in diabetes, obesity, and immune and inflammatory diseases for major pharmaceutical companies, in order to assist the companies in project selection and resource allocation decisions.
  • Assisted with initial planning for a major project to find novel approaches to drug discovery for a neurodegenerative disease.
  • Identified and assessed opportunities in the life sciences for a major Japanese producer of plastics products, including microfluidics and protein arrays. Further assessed opportunities for the application of protein arrays to drug discovery and diagnostics, devised market-entry and partnering strategies, and identified potential North American and European partners. As a result of our efforts, the client entered into an R&D collaboration with a leading U.S. developer of protein arrays.
  • Produced a proprietary report on recent advances in the area of human adult and embryonic stem cells for the research products division of a major corporation, and made recommendations on developing potential commercial opportunities in the stem cell area. Further assessed opportunities for the same client in leading edge cell culture technologies that are applicable to stem cell and developmental biology R&D, drug discovery, in vitro ADME-Tox, and tissue engineering.
  • Assessed opportunities in clinical genotyping applications of DNA microarrays for a leading U.S. corporate R&D laboratory contemplating a spin-off venture
  • Produced a proprietary report on recent developments in glycobiology, in order to assist a client to identify and assess potential business opportunities in that area.
  • Analyzed the market potential of a sample of likely early-stage products and services of a drug delivery start-up firm, in order to assist a technology incubator to determine the valuation of the company.
  • Performed due diligence on emerging and established biotechnology companies and their technologies and businesses for potential partner companies, as well as corporate funding and venture capital firms, in order to enable them to make informed partnering and investment decisions.